From Podium To Practice – Breast Cancer ESMO Part 9
Following progression on CDK4/6 inhibitor–based therapy, combination strategies are increasingly shaping the endocrine treatment landscape in HR-positive, HER2-negative metastatic breast cancer. In this conversation, Drs. Erica Mayer and Wassim Mchayleh review the VIKTORIA-1 trial, focusing on PI3K/AKT/mTOR pathway inhibition and the role of triplet versus doublet regimens in the wild-type population. They discuss key efficacy signals, toxicity considerations, and why moving beyond endocrine monotherapy is becoming essential for durable disease control in later lines of therapy.